AN2 Therapeutics presents SOHO 2026 data backing epetraborole development for polycythemia vera

• AN2 Therapeutics flagged new clinical and translational data supporting epetraborole as an oral candidate for polycythemia vera.
• Results will be presented at the SOHO 2026 Annual Meeting on Sept. 9-12 in Houston.
• Studies showed potential beneficial effects on red blood cell production and hemoglobin-related measures across healthy volunteers, non-PV patients, and primates.
• Nonhuman primate exposure-response patterns aligned with effects later seen in humans, supporting translational relevance for ongoing development in PV.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260831566807) on August 31, 2026, and is solely responsible for the information contained therein.